18/02/2026
Kenya has officially introduced Lenacapavir, a long-acting injectable drug designed to prevent HIV infection, marking a major step in the country’s fight against new cases.
The Ministry of Health confirmed that the new Pre-Exposure Prophylaxis (PrEP) option will give HIV-negative individuals protection for six months per dose, offering a powerful alternative to daily pills.
Kenya’s HIV prevalence stands at about 3.7 percent, with 1.34 million people on treatment. Alarmingly, 41 percent of new infections affect young people under 24.
The drug recently arrived at JKIA. Health officials said Lenacapavir, approved by the FDA and endorsed by WHO in 2025, blocks key stages of the virus life cycle.
Kenya has received 21,000 starter doses, funded by the Global Fund, with more supplies expected as rollout begins in 15 counties in March.